Research ArticleNeuropharmacology
Pharmacodynamics of Selective Inhibition of γ-Secretase by Avagacestat
Charles F. Albright, Randy C. Dockens, Jere E. Meredith Jr., Richard E. Olson, Randy Slemmon, Kimberley A. Lentz, Jun-Sheng Wang, R. Rex Denton, Gary Pilcher, Paul W. Rhyne, Joseph J. Raybon, Donna M. Barten, Catherine Burton, Jeremy H. Toyn, Sethu Sankaranarayanan, Craig Polson, Valerie Guss, Randy White, Frank Simutis, Thomas Sanderson, Kevin W. Gillman, John E. Starrett Jr., Joanne Bronson, Oleksandr Sverdlov, Shu-Pang Huang, Lorna Castaneda, Howard Feldman, Vlad Coric, Robert Zaczek, John E. Macor, John Houston, Robert M. Berman and Gary Tong
Journal of Pharmacology and Experimental Therapeutics March 2013, 344 (3) 686-695; DOI: https://doi.org/10.1124/jpet.112.199356
Charles F. Albright
Research and Development, Bristol-Myers Squibb, Wallingford, Connecticut (C.F.A., J.E.M., R.E.O., K.A.L., R.R.D., G.P., J.J.R., D.M.B., C.B., J.H.T., S.S., C.P., V.G., K.W.G., J.E.S., J.B., H.F., V.C., R.Z., J.E.M., J.H., R.M.B.); Research and Development, Bristol-Myers Squibb, Hopewell Facility, Pennington, New Jersey (R.D., R.S., G.T.); Research and Development, Bristol-Myers Squibb, Lawrenceville, New Jersey (J.-S.W., P.W.R., O.S., S.-P.H., L.C.); and Research and Development, Bristol-Myers Squibb, Department of Drug Safety Evaluation, Mount Vernon Facility, Evansville, Indiana (R.W., F.S., T.S.)
Randy C. Dockens
Research and Development, Bristol-Myers Squibb, Wallingford, Connecticut (C.F.A., J.E.M., R.E.O., K.A.L., R.R.D., G.P., J.J.R., D.M.B., C.B., J.H.T., S.S., C.P., V.G., K.W.G., J.E.S., J.B., H.F., V.C., R.Z., J.E.M., J.H., R.M.B.); Research and Development, Bristol-Myers Squibb, Hopewell Facility, Pennington, New Jersey (R.D., R.S., G.T.); Research and Development, Bristol-Myers Squibb, Lawrenceville, New Jersey (J.-S.W., P.W.R., O.S., S.-P.H., L.C.); and Research and Development, Bristol-Myers Squibb, Department of Drug Safety Evaluation, Mount Vernon Facility, Evansville, Indiana (R.W., F.S., T.S.)
Jere E. Meredith Jr.
Research and Development, Bristol-Myers Squibb, Wallingford, Connecticut (C.F.A., J.E.M., R.E.O., K.A.L., R.R.D., G.P., J.J.R., D.M.B., C.B., J.H.T., S.S., C.P., V.G., K.W.G., J.E.S., J.B., H.F., V.C., R.Z., J.E.M., J.H., R.M.B.); Research and Development, Bristol-Myers Squibb, Hopewell Facility, Pennington, New Jersey (R.D., R.S., G.T.); Research and Development, Bristol-Myers Squibb, Lawrenceville, New Jersey (J.-S.W., P.W.R., O.S., S.-P.H., L.C.); and Research and Development, Bristol-Myers Squibb, Department of Drug Safety Evaluation, Mount Vernon Facility, Evansville, Indiana (R.W., F.S., T.S.)
Richard E. Olson
Research and Development, Bristol-Myers Squibb, Wallingford, Connecticut (C.F.A., J.E.M., R.E.O., K.A.L., R.R.D., G.P., J.J.R., D.M.B., C.B., J.H.T., S.S., C.P., V.G., K.W.G., J.E.S., J.B., H.F., V.C., R.Z., J.E.M., J.H., R.M.B.); Research and Development, Bristol-Myers Squibb, Hopewell Facility, Pennington, New Jersey (R.D., R.S., G.T.); Research and Development, Bristol-Myers Squibb, Lawrenceville, New Jersey (J.-S.W., P.W.R., O.S., S.-P.H., L.C.); and Research and Development, Bristol-Myers Squibb, Department of Drug Safety Evaluation, Mount Vernon Facility, Evansville, Indiana (R.W., F.S., T.S.)
Randy Slemmon
Research and Development, Bristol-Myers Squibb, Wallingford, Connecticut (C.F.A., J.E.M., R.E.O., K.A.L., R.R.D., G.P., J.J.R., D.M.B., C.B., J.H.T., S.S., C.P., V.G., K.W.G., J.E.S., J.B., H.F., V.C., R.Z., J.E.M., J.H., R.M.B.); Research and Development, Bristol-Myers Squibb, Hopewell Facility, Pennington, New Jersey (R.D., R.S., G.T.); Research and Development, Bristol-Myers Squibb, Lawrenceville, New Jersey (J.-S.W., P.W.R., O.S., S.-P.H., L.C.); and Research and Development, Bristol-Myers Squibb, Department of Drug Safety Evaluation, Mount Vernon Facility, Evansville, Indiana (R.W., F.S., T.S.)
Kimberley A. Lentz
Research and Development, Bristol-Myers Squibb, Wallingford, Connecticut (C.F.A., J.E.M., R.E.O., K.A.L., R.R.D., G.P., J.J.R., D.M.B., C.B., J.H.T., S.S., C.P., V.G., K.W.G., J.E.S., J.B., H.F., V.C., R.Z., J.E.M., J.H., R.M.B.); Research and Development, Bristol-Myers Squibb, Hopewell Facility, Pennington, New Jersey (R.D., R.S., G.T.); Research and Development, Bristol-Myers Squibb, Lawrenceville, New Jersey (J.-S.W., P.W.R., O.S., S.-P.H., L.C.); and Research and Development, Bristol-Myers Squibb, Department of Drug Safety Evaluation, Mount Vernon Facility, Evansville, Indiana (R.W., F.S., T.S.)
Jun-Sheng Wang
Research and Development, Bristol-Myers Squibb, Wallingford, Connecticut (C.F.A., J.E.M., R.E.O., K.A.L., R.R.D., G.P., J.J.R., D.M.B., C.B., J.H.T., S.S., C.P., V.G., K.W.G., J.E.S., J.B., H.F., V.C., R.Z., J.E.M., J.H., R.M.B.); Research and Development, Bristol-Myers Squibb, Hopewell Facility, Pennington, New Jersey (R.D., R.S., G.T.); Research and Development, Bristol-Myers Squibb, Lawrenceville, New Jersey (J.-S.W., P.W.R., O.S., S.-P.H., L.C.); and Research and Development, Bristol-Myers Squibb, Department of Drug Safety Evaluation, Mount Vernon Facility, Evansville, Indiana (R.W., F.S., T.S.)
R. Rex Denton
Research and Development, Bristol-Myers Squibb, Wallingford, Connecticut (C.F.A., J.E.M., R.E.O., K.A.L., R.R.D., G.P., J.J.R., D.M.B., C.B., J.H.T., S.S., C.P., V.G., K.W.G., J.E.S., J.B., H.F., V.C., R.Z., J.E.M., J.H., R.M.B.); Research and Development, Bristol-Myers Squibb, Hopewell Facility, Pennington, New Jersey (R.D., R.S., G.T.); Research and Development, Bristol-Myers Squibb, Lawrenceville, New Jersey (J.-S.W., P.W.R., O.S., S.-P.H., L.C.); and Research and Development, Bristol-Myers Squibb, Department of Drug Safety Evaluation, Mount Vernon Facility, Evansville, Indiana (R.W., F.S., T.S.)
Gary Pilcher
Research and Development, Bristol-Myers Squibb, Wallingford, Connecticut (C.F.A., J.E.M., R.E.O., K.A.L., R.R.D., G.P., J.J.R., D.M.B., C.B., J.H.T., S.S., C.P., V.G., K.W.G., J.E.S., J.B., H.F., V.C., R.Z., J.E.M., J.H., R.M.B.); Research and Development, Bristol-Myers Squibb, Hopewell Facility, Pennington, New Jersey (R.D., R.S., G.T.); Research and Development, Bristol-Myers Squibb, Lawrenceville, New Jersey (J.-S.W., P.W.R., O.S., S.-P.H., L.C.); and Research and Development, Bristol-Myers Squibb, Department of Drug Safety Evaluation, Mount Vernon Facility, Evansville, Indiana (R.W., F.S., T.S.)
Paul W. Rhyne
Research and Development, Bristol-Myers Squibb, Wallingford, Connecticut (C.F.A., J.E.M., R.E.O., K.A.L., R.R.D., G.P., J.J.R., D.M.B., C.B., J.H.T., S.S., C.P., V.G., K.W.G., J.E.S., J.B., H.F., V.C., R.Z., J.E.M., J.H., R.M.B.); Research and Development, Bristol-Myers Squibb, Hopewell Facility, Pennington, New Jersey (R.D., R.S., G.T.); Research and Development, Bristol-Myers Squibb, Lawrenceville, New Jersey (J.-S.W., P.W.R., O.S., S.-P.H., L.C.); and Research and Development, Bristol-Myers Squibb, Department of Drug Safety Evaluation, Mount Vernon Facility, Evansville, Indiana (R.W., F.S., T.S.)
Joseph J. Raybon
Research and Development, Bristol-Myers Squibb, Wallingford, Connecticut (C.F.A., J.E.M., R.E.O., K.A.L., R.R.D., G.P., J.J.R., D.M.B., C.B., J.H.T., S.S., C.P., V.G., K.W.G., J.E.S., J.B., H.F., V.C., R.Z., J.E.M., J.H., R.M.B.); Research and Development, Bristol-Myers Squibb, Hopewell Facility, Pennington, New Jersey (R.D., R.S., G.T.); Research and Development, Bristol-Myers Squibb, Lawrenceville, New Jersey (J.-S.W., P.W.R., O.S., S.-P.H., L.C.); and Research and Development, Bristol-Myers Squibb, Department of Drug Safety Evaluation, Mount Vernon Facility, Evansville, Indiana (R.W., F.S., T.S.)
Donna M. Barten
Research and Development, Bristol-Myers Squibb, Wallingford, Connecticut (C.F.A., J.E.M., R.E.O., K.A.L., R.R.D., G.P., J.J.R., D.M.B., C.B., J.H.T., S.S., C.P., V.G., K.W.G., J.E.S., J.B., H.F., V.C., R.Z., J.E.M., J.H., R.M.B.); Research and Development, Bristol-Myers Squibb, Hopewell Facility, Pennington, New Jersey (R.D., R.S., G.T.); Research and Development, Bristol-Myers Squibb, Lawrenceville, New Jersey (J.-S.W., P.W.R., O.S., S.-P.H., L.C.); and Research and Development, Bristol-Myers Squibb, Department of Drug Safety Evaluation, Mount Vernon Facility, Evansville, Indiana (R.W., F.S., T.S.)
Catherine Burton
Research and Development, Bristol-Myers Squibb, Wallingford, Connecticut (C.F.A., J.E.M., R.E.O., K.A.L., R.R.D., G.P., J.J.R., D.M.B., C.B., J.H.T., S.S., C.P., V.G., K.W.G., J.E.S., J.B., H.F., V.C., R.Z., J.E.M., J.H., R.M.B.); Research and Development, Bristol-Myers Squibb, Hopewell Facility, Pennington, New Jersey (R.D., R.S., G.T.); Research and Development, Bristol-Myers Squibb, Lawrenceville, New Jersey (J.-S.W., P.W.R., O.S., S.-P.H., L.C.); and Research and Development, Bristol-Myers Squibb, Department of Drug Safety Evaluation, Mount Vernon Facility, Evansville, Indiana (R.W., F.S., T.S.)
Jeremy H. Toyn
Research and Development, Bristol-Myers Squibb, Wallingford, Connecticut (C.F.A., J.E.M., R.E.O., K.A.L., R.R.D., G.P., J.J.R., D.M.B., C.B., J.H.T., S.S., C.P., V.G., K.W.G., J.E.S., J.B., H.F., V.C., R.Z., J.E.M., J.H., R.M.B.); Research and Development, Bristol-Myers Squibb, Hopewell Facility, Pennington, New Jersey (R.D., R.S., G.T.); Research and Development, Bristol-Myers Squibb, Lawrenceville, New Jersey (J.-S.W., P.W.R., O.S., S.-P.H., L.C.); and Research and Development, Bristol-Myers Squibb, Department of Drug Safety Evaluation, Mount Vernon Facility, Evansville, Indiana (R.W., F.S., T.S.)
Sethu Sankaranarayanan
Research and Development, Bristol-Myers Squibb, Wallingford, Connecticut (C.F.A., J.E.M., R.E.O., K.A.L., R.R.D., G.P., J.J.R., D.M.B., C.B., J.H.T., S.S., C.P., V.G., K.W.G., J.E.S., J.B., H.F., V.C., R.Z., J.E.M., J.H., R.M.B.); Research and Development, Bristol-Myers Squibb, Hopewell Facility, Pennington, New Jersey (R.D., R.S., G.T.); Research and Development, Bristol-Myers Squibb, Lawrenceville, New Jersey (J.-S.W., P.W.R., O.S., S.-P.H., L.C.); and Research and Development, Bristol-Myers Squibb, Department of Drug Safety Evaluation, Mount Vernon Facility, Evansville, Indiana (R.W., F.S., T.S.)
Craig Polson
Research and Development, Bristol-Myers Squibb, Wallingford, Connecticut (C.F.A., J.E.M., R.E.O., K.A.L., R.R.D., G.P., J.J.R., D.M.B., C.B., J.H.T., S.S., C.P., V.G., K.W.G., J.E.S., J.B., H.F., V.C., R.Z., J.E.M., J.H., R.M.B.); Research and Development, Bristol-Myers Squibb, Hopewell Facility, Pennington, New Jersey (R.D., R.S., G.T.); Research and Development, Bristol-Myers Squibb, Lawrenceville, New Jersey (J.-S.W., P.W.R., O.S., S.-P.H., L.C.); and Research and Development, Bristol-Myers Squibb, Department of Drug Safety Evaluation, Mount Vernon Facility, Evansville, Indiana (R.W., F.S., T.S.)
Valerie Guss
Research and Development, Bristol-Myers Squibb, Wallingford, Connecticut (C.F.A., J.E.M., R.E.O., K.A.L., R.R.D., G.P., J.J.R., D.M.B., C.B., J.H.T., S.S., C.P., V.G., K.W.G., J.E.S., J.B., H.F., V.C., R.Z., J.E.M., J.H., R.M.B.); Research and Development, Bristol-Myers Squibb, Hopewell Facility, Pennington, New Jersey (R.D., R.S., G.T.); Research and Development, Bristol-Myers Squibb, Lawrenceville, New Jersey (J.-S.W., P.W.R., O.S., S.-P.H., L.C.); and Research and Development, Bristol-Myers Squibb, Department of Drug Safety Evaluation, Mount Vernon Facility, Evansville, Indiana (R.W., F.S., T.S.)
Randy White
Research and Development, Bristol-Myers Squibb, Wallingford, Connecticut (C.F.A., J.E.M., R.E.O., K.A.L., R.R.D., G.P., J.J.R., D.M.B., C.B., J.H.T., S.S., C.P., V.G., K.W.G., J.E.S., J.B., H.F., V.C., R.Z., J.E.M., J.H., R.M.B.); Research and Development, Bristol-Myers Squibb, Hopewell Facility, Pennington, New Jersey (R.D., R.S., G.T.); Research and Development, Bristol-Myers Squibb, Lawrenceville, New Jersey (J.-S.W., P.W.R., O.S., S.-P.H., L.C.); and Research and Development, Bristol-Myers Squibb, Department of Drug Safety Evaluation, Mount Vernon Facility, Evansville, Indiana (R.W., F.S., T.S.)
Frank Simutis
Research and Development, Bristol-Myers Squibb, Wallingford, Connecticut (C.F.A., J.E.M., R.E.O., K.A.L., R.R.D., G.P., J.J.R., D.M.B., C.B., J.H.T., S.S., C.P., V.G., K.W.G., J.E.S., J.B., H.F., V.C., R.Z., J.E.M., J.H., R.M.B.); Research and Development, Bristol-Myers Squibb, Hopewell Facility, Pennington, New Jersey (R.D., R.S., G.T.); Research and Development, Bristol-Myers Squibb, Lawrenceville, New Jersey (J.-S.W., P.W.R., O.S., S.-P.H., L.C.); and Research and Development, Bristol-Myers Squibb, Department of Drug Safety Evaluation, Mount Vernon Facility, Evansville, Indiana (R.W., F.S., T.S.)
Thomas Sanderson
Research and Development, Bristol-Myers Squibb, Wallingford, Connecticut (C.F.A., J.E.M., R.E.O., K.A.L., R.R.D., G.P., J.J.R., D.M.B., C.B., J.H.T., S.S., C.P., V.G., K.W.G., J.E.S., J.B., H.F., V.C., R.Z., J.E.M., J.H., R.M.B.); Research and Development, Bristol-Myers Squibb, Hopewell Facility, Pennington, New Jersey (R.D., R.S., G.T.); Research and Development, Bristol-Myers Squibb, Lawrenceville, New Jersey (J.-S.W., P.W.R., O.S., S.-P.H., L.C.); and Research and Development, Bristol-Myers Squibb, Department of Drug Safety Evaluation, Mount Vernon Facility, Evansville, Indiana (R.W., F.S., T.S.)
Kevin W. Gillman
Research and Development, Bristol-Myers Squibb, Wallingford, Connecticut (C.F.A., J.E.M., R.E.O., K.A.L., R.R.D., G.P., J.J.R., D.M.B., C.B., J.H.T., S.S., C.P., V.G., K.W.G., J.E.S., J.B., H.F., V.C., R.Z., J.E.M., J.H., R.M.B.); Research and Development, Bristol-Myers Squibb, Hopewell Facility, Pennington, New Jersey (R.D., R.S., G.T.); Research and Development, Bristol-Myers Squibb, Lawrenceville, New Jersey (J.-S.W., P.W.R., O.S., S.-P.H., L.C.); and Research and Development, Bristol-Myers Squibb, Department of Drug Safety Evaluation, Mount Vernon Facility, Evansville, Indiana (R.W., F.S., T.S.)
John E. Starrett Jr.
Research and Development, Bristol-Myers Squibb, Wallingford, Connecticut (C.F.A., J.E.M., R.E.O., K.A.L., R.R.D., G.P., J.J.R., D.M.B., C.B., J.H.T., S.S., C.P., V.G., K.W.G., J.E.S., J.B., H.F., V.C., R.Z., J.E.M., J.H., R.M.B.); Research and Development, Bristol-Myers Squibb, Hopewell Facility, Pennington, New Jersey (R.D., R.S., G.T.); Research and Development, Bristol-Myers Squibb, Lawrenceville, New Jersey (J.-S.W., P.W.R., O.S., S.-P.H., L.C.); and Research and Development, Bristol-Myers Squibb, Department of Drug Safety Evaluation, Mount Vernon Facility, Evansville, Indiana (R.W., F.S., T.S.)
Joanne Bronson
Research and Development, Bristol-Myers Squibb, Wallingford, Connecticut (C.F.A., J.E.M., R.E.O., K.A.L., R.R.D., G.P., J.J.R., D.M.B., C.B., J.H.T., S.S., C.P., V.G., K.W.G., J.E.S., J.B., H.F., V.C., R.Z., J.E.M., J.H., R.M.B.); Research and Development, Bristol-Myers Squibb, Hopewell Facility, Pennington, New Jersey (R.D., R.S., G.T.); Research and Development, Bristol-Myers Squibb, Lawrenceville, New Jersey (J.-S.W., P.W.R., O.S., S.-P.H., L.C.); and Research and Development, Bristol-Myers Squibb, Department of Drug Safety Evaluation, Mount Vernon Facility, Evansville, Indiana (R.W., F.S., T.S.)
Oleksandr Sverdlov
Research and Development, Bristol-Myers Squibb, Wallingford, Connecticut (C.F.A., J.E.M., R.E.O., K.A.L., R.R.D., G.P., J.J.R., D.M.B., C.B., J.H.T., S.S., C.P., V.G., K.W.G., J.E.S., J.B., H.F., V.C., R.Z., J.E.M., J.H., R.M.B.); Research and Development, Bristol-Myers Squibb, Hopewell Facility, Pennington, New Jersey (R.D., R.S., G.T.); Research and Development, Bristol-Myers Squibb, Lawrenceville, New Jersey (J.-S.W., P.W.R., O.S., S.-P.H., L.C.); and Research and Development, Bristol-Myers Squibb, Department of Drug Safety Evaluation, Mount Vernon Facility, Evansville, Indiana (R.W., F.S., T.S.)
Shu-Pang Huang
Research and Development, Bristol-Myers Squibb, Wallingford, Connecticut (C.F.A., J.E.M., R.E.O., K.A.L., R.R.D., G.P., J.J.R., D.M.B., C.B., J.H.T., S.S., C.P., V.G., K.W.G., J.E.S., J.B., H.F., V.C., R.Z., J.E.M., J.H., R.M.B.); Research and Development, Bristol-Myers Squibb, Hopewell Facility, Pennington, New Jersey (R.D., R.S., G.T.); Research and Development, Bristol-Myers Squibb, Lawrenceville, New Jersey (J.-S.W., P.W.R., O.S., S.-P.H., L.C.); and Research and Development, Bristol-Myers Squibb, Department of Drug Safety Evaluation, Mount Vernon Facility, Evansville, Indiana (R.W., F.S., T.S.)
Lorna Castaneda
Research and Development, Bristol-Myers Squibb, Wallingford, Connecticut (C.F.A., J.E.M., R.E.O., K.A.L., R.R.D., G.P., J.J.R., D.M.B., C.B., J.H.T., S.S., C.P., V.G., K.W.G., J.E.S., J.B., H.F., V.C., R.Z., J.E.M., J.H., R.M.B.); Research and Development, Bristol-Myers Squibb, Hopewell Facility, Pennington, New Jersey (R.D., R.S., G.T.); Research and Development, Bristol-Myers Squibb, Lawrenceville, New Jersey (J.-S.W., P.W.R., O.S., S.-P.H., L.C.); and Research and Development, Bristol-Myers Squibb, Department of Drug Safety Evaluation, Mount Vernon Facility, Evansville, Indiana (R.W., F.S., T.S.)
Howard Feldman
Research and Development, Bristol-Myers Squibb, Wallingford, Connecticut (C.F.A., J.E.M., R.E.O., K.A.L., R.R.D., G.P., J.J.R., D.M.B., C.B., J.H.T., S.S., C.P., V.G., K.W.G., J.E.S., J.B., H.F., V.C., R.Z., J.E.M., J.H., R.M.B.); Research and Development, Bristol-Myers Squibb, Hopewell Facility, Pennington, New Jersey (R.D., R.S., G.T.); Research and Development, Bristol-Myers Squibb, Lawrenceville, New Jersey (J.-S.W., P.W.R., O.S., S.-P.H., L.C.); and Research and Development, Bristol-Myers Squibb, Department of Drug Safety Evaluation, Mount Vernon Facility, Evansville, Indiana (R.W., F.S., T.S.)
Vlad Coric
Research and Development, Bristol-Myers Squibb, Wallingford, Connecticut (C.F.A., J.E.M., R.E.O., K.A.L., R.R.D., G.P., J.J.R., D.M.B., C.B., J.H.T., S.S., C.P., V.G., K.W.G., J.E.S., J.B., H.F., V.C., R.Z., J.E.M., J.H., R.M.B.); Research and Development, Bristol-Myers Squibb, Hopewell Facility, Pennington, New Jersey (R.D., R.S., G.T.); Research and Development, Bristol-Myers Squibb, Lawrenceville, New Jersey (J.-S.W., P.W.R., O.S., S.-P.H., L.C.); and Research and Development, Bristol-Myers Squibb, Department of Drug Safety Evaluation, Mount Vernon Facility, Evansville, Indiana (R.W., F.S., T.S.)
Robert Zaczek
Research and Development, Bristol-Myers Squibb, Wallingford, Connecticut (C.F.A., J.E.M., R.E.O., K.A.L., R.R.D., G.P., J.J.R., D.M.B., C.B., J.H.T., S.S., C.P., V.G., K.W.G., J.E.S., J.B., H.F., V.C., R.Z., J.E.M., J.H., R.M.B.); Research and Development, Bristol-Myers Squibb, Hopewell Facility, Pennington, New Jersey (R.D., R.S., G.T.); Research and Development, Bristol-Myers Squibb, Lawrenceville, New Jersey (J.-S.W., P.W.R., O.S., S.-P.H., L.C.); and Research and Development, Bristol-Myers Squibb, Department of Drug Safety Evaluation, Mount Vernon Facility, Evansville, Indiana (R.W., F.S., T.S.)
John E. Macor
Research and Development, Bristol-Myers Squibb, Wallingford, Connecticut (C.F.A., J.E.M., R.E.O., K.A.L., R.R.D., G.P., J.J.R., D.M.B., C.B., J.H.T., S.S., C.P., V.G., K.W.G., J.E.S., J.B., H.F., V.C., R.Z., J.E.M., J.H., R.M.B.); Research and Development, Bristol-Myers Squibb, Hopewell Facility, Pennington, New Jersey (R.D., R.S., G.T.); Research and Development, Bristol-Myers Squibb, Lawrenceville, New Jersey (J.-S.W., P.W.R., O.S., S.-P.H., L.C.); and Research and Development, Bristol-Myers Squibb, Department of Drug Safety Evaluation, Mount Vernon Facility, Evansville, Indiana (R.W., F.S., T.S.)
John Houston
Research and Development, Bristol-Myers Squibb, Wallingford, Connecticut (C.F.A., J.E.M., R.E.O., K.A.L., R.R.D., G.P., J.J.R., D.M.B., C.B., J.H.T., S.S., C.P., V.G., K.W.G., J.E.S., J.B., H.F., V.C., R.Z., J.E.M., J.H., R.M.B.); Research and Development, Bristol-Myers Squibb, Hopewell Facility, Pennington, New Jersey (R.D., R.S., G.T.); Research and Development, Bristol-Myers Squibb, Lawrenceville, New Jersey (J.-S.W., P.W.R., O.S., S.-P.H., L.C.); and Research and Development, Bristol-Myers Squibb, Department of Drug Safety Evaluation, Mount Vernon Facility, Evansville, Indiana (R.W., F.S., T.S.)
Robert M. Berman
Research and Development, Bristol-Myers Squibb, Wallingford, Connecticut (C.F.A., J.E.M., R.E.O., K.A.L., R.R.D., G.P., J.J.R., D.M.B., C.B., J.H.T., S.S., C.P., V.G., K.W.G., J.E.S., J.B., H.F., V.C., R.Z., J.E.M., J.H., R.M.B.); Research and Development, Bristol-Myers Squibb, Hopewell Facility, Pennington, New Jersey (R.D., R.S., G.T.); Research and Development, Bristol-Myers Squibb, Lawrenceville, New Jersey (J.-S.W., P.W.R., O.S., S.-P.H., L.C.); and Research and Development, Bristol-Myers Squibb, Department of Drug Safety Evaluation, Mount Vernon Facility, Evansville, Indiana (R.W., F.S., T.S.)
Gary Tong
Research and Development, Bristol-Myers Squibb, Wallingford, Connecticut (C.F.A., J.E.M., R.E.O., K.A.L., R.R.D., G.P., J.J.R., D.M.B., C.B., J.H.T., S.S., C.P., V.G., K.W.G., J.E.S., J.B., H.F., V.C., R.Z., J.E.M., J.H., R.M.B.); Research and Development, Bristol-Myers Squibb, Hopewell Facility, Pennington, New Jersey (R.D., R.S., G.T.); Research and Development, Bristol-Myers Squibb, Lawrenceville, New Jersey (J.-S.W., P.W.R., O.S., S.-P.H., L.C.); and Research and Development, Bristol-Myers Squibb, Department of Drug Safety Evaluation, Mount Vernon Facility, Evansville, Indiana (R.W., F.S., T.S.)
Submit a Response to This Article
Jump to comment:
No eLetters have been published for this article.
In this issue
Research ArticleNeuropharmacology
Pharmacodynamics of γ-Secretase Inhibition by Avagacestat
Charles F. Albright, Randy C. Dockens, Jere E. Meredith, Richard E. Olson, Randy Slemmon, Kimberley A. Lentz, Jun-Sheng Wang, R. Rex Denton, Gary Pilcher, Paul W. Rhyne, Joseph J. Raybon, Donna M. Barten, Catherine Burton, Jeremy H. Toyn, Sethu Sankaranarayanan, Craig Polson, Valerie Guss, Randy White, Frank Simutis, Thomas Sanderson, Kevin W. Gillman, John E. Starrett, Joanne Bronson, Oleksandr Sverdlov, Shu-Pang Huang, Lorna Castaneda, Howard Feldman, Vlad Coric, Robert Zaczek, John E. Macor, John Houston, Robert M. Berman and Gary Tong
Journal of Pharmacology and Experimental Therapeutics March 1, 2013, 344 (3) 686-695; DOI: https://doi.org/10.1124/jpet.112.199356
Research ArticleNeuropharmacology
Pharmacodynamics of γ-Secretase Inhibition by Avagacestat
Charles F. Albright, Randy C. Dockens, Jere E. Meredith, Richard E. Olson, Randy Slemmon, Kimberley A. Lentz, Jun-Sheng Wang, R. Rex Denton, Gary Pilcher, Paul W. Rhyne, Joseph J. Raybon, Donna M. Barten, Catherine Burton, Jeremy H. Toyn, Sethu Sankaranarayanan, Craig Polson, Valerie Guss, Randy White, Frank Simutis, Thomas Sanderson, Kevin W. Gillman, John E. Starrett, Joanne Bronson, Oleksandr Sverdlov, Shu-Pang Huang, Lorna Castaneda, Howard Feldman, Vlad Coric, Robert Zaczek, John E. Macor, John Houston, Robert M. Berman and Gary Tong
Journal of Pharmacology and Experimental Therapeutics March 1, 2013, 344 (3) 686-695; DOI: https://doi.org/10.1124/jpet.112.199356
Jump to section
Related Articles
Cited By...
More in this TOC Section
Similar Articles
Advertisement